Welcome to our dedicated page for Mind Medicine SEC filings (Ticker: MNMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates for brain health disorders, and its filings offer detailed information on clinical progress, financing transactions and corporate matters.
Through Forms 8‑K, MindMed reports material events such as underwritten public offerings of common shares under its shelf registration statement on Form S‑3, entry into underwriting agreements, and the intended use of proceeds to fund research and development, working capital and general corporate purposes. Other 8‑K filings describe the release of quarterly financial results, updated corporate presentations, and announcements related to clinical and scientific milestones, including publication of MM120 trial data in generalized anxiety disorder.
MindMed’s filings also identify its jurisdiction of incorporation in British Columbia, Canada, its listing of common shares on The Nasdaq Stock Market LLC under the symbol MNMD, and its status as an emerging growth company. Investors can use this page to review prospectus supplements, opinions and exhibits referenced in 8‑K filings, as well as periodic reports such as Forms 10‑K and 10‑Q accessed via EDGAR.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, such as the terms of public offerings, changes in cash and investments, and updates on the development of MM120 and MM402. Real-time updates from EDGAR, along with structured access to Forms 10‑K, 10‑Q and 4, help users quickly locate information on MindMed’s financial condition, capital structure and insider-related disclosures.
Dan Karlin, Chief Medical Officer of Mind Medicine (MNMD), reported a transaction dated 09/25/2025 in which 7,704 common shares were disposed of at $9.77 per share. The filing states these shares were sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units under a Rule 10b5-1 plan adopted on June 14, 2022. After the reported disposition, the reporting person beneficially owns 430,625 common shares. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Karlin on 09/26/2025.
Mind Medicine (MNMD) Form 144 notice discloses a proposed sale of 11,278 common shares by an insider through Morgan Stanley Smith Barney, with an aggregate market value of $110,216.51. The filer indicates the shares were acquired on 09/25/2025 as restricted stock vesting under a registered plan and the intended method of payment is compensation. The sale is listed with an approximate sale date of 09/25/2025 on NASDAQ. The filing also reports a prior sale by Mark Sullivan of 11,491 shares on 06/25/2025 for $78,169.83. The notice includes the standard insider representation about lack of undisclosed material information.
Mind Medicine (MNMD) Form 144 shows an intended sale of 7,704 common shares by a person for whose account the securities were issued, through Morgan Stanley Smith Barney LLC on 09/25/2025 on NASDAQ. The filing reports an aggregate market value of $75,288.88 for the shares and lists 76,087,943 shares outstanding for the issuer. The shares to be sold were acquired the same day, 09/25/2025, as restricted stock vesting under a registered plan and payment is recorded as Not Applicable. The filing also discloses a prior sale by DANIEL ROLLINGS KARLIN of 7,848 shares on 06/25/2025 for gross proceeds of $53,387.59. The notice includes the required signature representation regarding absence of undisclosed material adverse information.
Form 144 notice for Mind Medicine (MNMD): The filing records a proposed sale of 25,797 common shares with an aggregate market value of $252,106.34 through Morgan Stanley Smith Barney LLC on 09/25/2025 on Nasdaq. The shares were acquired the same day as restricted stock vesting under a registered plan and payment is listed as Not Applicable. The form also discloses a prior sale by Robert B Barrow of 26,491 shares on 06/25/2025 for gross proceeds of $180,210.33. The filer attests there is no undisclosed material adverse information and the standard signature and legal warning language appear.
Mind Medicine (MindMed) Inc. filed a report stating that it has issued a press release about new clinical data. On September 4, 2025, the company announced the publication of results from its Phase 2b clinical trial of MM120 (Lysergide D-Tartrate) for Generalized Anxiety Disorder in the Journal of the American Medical Association. The related press release is included as an exhibit to provide more detail on the trial results and their context.
Mind Medicine (MindMed) Inc. (MNMD) – Form 4 insider transaction:
Chief Legal Officer Mark Sullivan reported the sale of 11,491 common shares on 25-Jun-2025. The shares were automatically sold (transaction code “S”) to cover withholding-tax liabilities triggered by the settlement of vested RSUs. The disposition was executed under a Rule 10b5-1 plan adopted 14-Mar-2024, indicating the trade was pre-scheduled and not discretionary.
The weighted-average sales price was $6.80, with individual trades carried out between $6.67 and $7.03. After the sale, Sullivan directly owns 305,130 shares, meaning the transaction reduced his position by roughly 3.6 %. No derivative securities were involved, and the filing was signed on 26-Jun-2025.
- The activity appears routine, tax-driven and represents a small fraction of the executive’s holdings.
- Provides investors with an indicative trading range for MNMD at the end of June 2025.
Given the limited size and tax-related nature, the sale is unlikely to carry significant fundamental implications, though it is the first insider disposition tied to this RSU vesting cycle.
MindMed (NASDAQ: MNMD) filed a Form 4 showing CEO & Director Robert Barrow sold 26,491 common shares on 25 Jun 2025 at a weighted-average price of $6.80. The sale, made under a pre-arranged Rule 10b5-1 plan, was solely to cover withholding taxes on recently vested RSUs. After the transaction, Barrow retains 830,065 shares of MindMed. No other insider trades or material changes were disclosed.